ABBV•benzinga•
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Summary
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga